Kura Oncology Showcases Key Data from KOMET-007 Trial at ASH Meeting
Kura Oncology, Inc. (NASDAQ: KURA), a biopharmaceutical company focused on developing innovative cancer treatments, has announced the presentation of significant clinical data from the KOMET-007 trial of ziftomenib at the upcoming American Society of Hematology (ASH) Annual Meeting. This recognition highlights the potential of ziftomenib, a selective menin inhibitor, in both newly diagnosed and relapsed/refractory acute myeloid leukemia (AML) patients.
Overview of the KOMET-007 Trial
The KOMET-007 trial is a multicenter Phase 1 study assessing the combination of ziftomenib with standard AML treatments, namely the 7+3 regimen of cytarabine and daunorubicin, as well as venetoclax combined with azacitidine (ven/aza). Targeted towards patients exhibiting NPM1 mutations and KMT2A rearrangements, the trial aims to evaluate the safety and efficacy of ziftomenib under varying patient conditions.
Significant Findings to be Presented
During the ASH Annual Meeting, Kura Oncology will present interim results that showcase ziftomenib's performance in these challenging patient cohorts. Notably, all four cohorts in the early dose-escalation phase have progressed into the expansion stage at the 600 mg dose level. This achievement suggests a strong safety profile and enduring activity of ziftomenib when combined with established treatments.
Executive Insights on Treatment Potential
Troy Wilson, Ph.D., J.D., President and CEO of Kura Oncology, expressed optimism regarding ziftomenib’s promising safety and tolerability, as well as its robust activity in combination with ven/aza treatments. He stated that while treating relapsed/refractory AML patients, ziftomenib showcased no dose-limiting toxicities (DLTs) and no adverse QTc prolongation events. Additionally, incidences of differentiation syndrome have been minimized with the combination therapy.
Details of ASH Presentation Sessions
Kura will present two abstracts at the ASH Annual Meeting:
- Ziftomenib Combined with Intensive Induction (7+3) in Newly Diagnosed NPM1-m or KMT2A-r Acute Myeloid Leukemia: Interim Phase 1a Results
Session: 616, focusing on investigational drug and cellular therapies, will be presented as an oral session on December 7, 2024. - Ziftomenib Combined with Venetoclax/Azacitidine in Relapsed/Refractory NPM1-m or KMT2A-r Acute Myeloid Leukemia: Interim Phase 1a Results
This poster session will take place on December 8, 2024.
About Kura Oncology and Its Innovative Approach
Kura Oncology is committed to developing precision medicines to combat cancer, with a robust pipeline featuring small molecule candidates that target key signaling pathways associated with tumor growth. Ziftomenib, which has garnered Breakthrough Therapy Designation, is a promising treatment in clinical trials for patients with R/R NPM1-m AML. The company continues to advance its clinical programs, including research into combination therapies that seek to enhance treatment efficacy in diverse cancer types.
Frequently Asked Questions
What is the purpose of the KOMET-007 trial?
The KOMET-007 trial evaluates ziftomenib’s safety and efficacy in AML patients, specifically those with NPM1 mutations or KMT2A rearrangements, in combination with standard treatments.
What has been the response to ziftomenib in clinical trials?
Clinical data suggest that ziftomenib is well-tolerated and shows encouraging activity, even in patients previously treated with other therapies.
When will presentation details be available?
The information for the presentations will be featured on Kura's website following the ASH conference.
What is ziftomenib's status in the development pipeline?
Ziftomenib has received Breakthrough Therapy Designation and is being actively studied in various clinical trials to assess its effectiveness in AML.
How can I learn more about Kura Oncology's research?
For more information on current studies and developments, visit Kura's official website.
